Tuesday's Winners and Losers: Directed Electronics

A clear winner for the day, vehicle accessories maker Directed Electronics (DEIX Quote), blasted off 44.1% to $1.60 after announcing an extension of its contract with Sirius Satellite Radio (SIRI Quote). Hailing from Vista, Calif., Direct Electronics manufactures receivers to carry broadcasts from Sirius(SIRI Quote), shares of which rose 1.7% to $3.56.

Among the day's big decliners was embattled headwear and footwear merchant Genesco (GCO Quote). The Nashville, Tenn., company received a subpoena from U.S. prosecutors pertaining to its merger with fellow footwear retailer Finish Line (FINL Quote). Prosecutors seek documents connected to alleged violation of federal fraud statutes. Genesco shares fell 15.3% to $25.57, while shares of Finish Line gained 7.8% to $3.17.

Shares of video-game publisher Activision(ATVI Quote) soared after the company raised its revenue and earnings outlook for the third quarter and fiscal year based on strong retail sales over the Thanksgiving weekend. Activision's two big releases this quarter, Guitar Hero III: Legends of Rock and Call of Duty 4, are expected to drive sales this holiday season. Shares of Activision were up $2.61, or 13.8%, to $21.54.

VMware(VMW Quote) bounced back after a fall Monday resulting from an analyst report that suggested the stock is overvalued. Shares of VMware were up $6.14, or 8.6%, to $77.58. EMC(EMC Quote), which holds an 86% stake in VMware, was up 82 cents, or 4.7% to $18.19.

Barrier Therapeutics(BTRX Quote) rose 42 cents, or 12.4%, to $3.78 after announcing positive results from a safety, dose-escalation study of its oral antifungal drug, pramiconazole. The company used a 6-gram dose, 30 times higher than the single weekly dose that's currently being used in a phase IIa study in toenail fungus. Barrier said that no clinically relevant changes were seen in 32 volunteers dosed with up to 6 grams of the drug over a five-day period compared to placebo.

Osiris Therapeutics(OSIR Quote) gave positive interim, one-year results of a 55-patient, phase I/II trial evaluating Chondrogen, a preparation of adult stem cells formulated to be injected into the knee. The company said the one-year data showed improvement in joint condition and that patients with osteoarthritis who were treated with Chrondrogen saw clinically and statistically significant improvement in pain compared to those treated with hyaluronic acid, the control. Shares rose $1.53, or 15%, to $11.77.